Economic Burden of Propionic Acidemia by Age Stratum in the United States
Author(s)
Banerjee G1, Mu F2, Cheng M2, Cook E2, Zhang A2, Lan JJ2, Zou L2, Sikirica V3
1ModernaTX, Inc., Cambridge, MA, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Moderna, Inc., Cambridge, MA, USA
Presentation Documents
OBJECTIVES: To estimate the economic burden of propionic acidemia (PA), a rare inherited metabolic disorder, in the United States by age stratum.
METHODS: A retrospective matched cohort study was conducted using IQVIA PharMetrics® Plus claims data (10/2015-06/2022) comparing patients with PA to patients without PA (controls). Patients were matched 1:1 within each age stratum (0-2, 3-6, 7-12, 13-17, and 18+ years) on factors including age, year, month, sex, region, and insurance. All-cause healthcare resource utilization (HRU) per patient-year (PPY) and annualized costs were described and compared between patients with and without PA within age strata.
RESULTS: This study included 191 patients with PA and their matched controls (by age stratum: 0-2 years, n=32 pairs; 3-6, n=32; 7-12, n=36; 13-17, n=24; 18+, n=106). Most patients had commercial insurance (91.1%) and half were female (49.7%). Patients with PA had significantly higher HRU rates and total costs compared to controls across age strata. Patients with PA had 0.5-2.3 hospitalizations, 0.7-1.9 emergency visits, and 15.3-41.3 outpatient visits PPY across age strata, leading to a 10.4-78.6, 2.2-4.5, and 1.9-8.2 fold higher rate compared to controls, respectively (all p<0.001). Mean (median) total healthcare costs were $88,523 ($16,929) among patients with PA, with medical costs accounting for about 68% of total costs ($60,385 [$14,674]), primarily driven by hospitalization costs ($40,621 [$3,254]). Total mean annualized cost difference was highest for patients with PA at 0-2 years vs. controls at $205,883 ($209,332 [$42,991] vs. $3,449 [$2,711]) and lowest at 7-12 years at $20,169 ($21,797 [$11,487] vs. $1,628 [$617]); adults also showed a significant difference at $75,095 ($79,336 [$21,168] vs. $4,241 [$1,437]) (all p<0.001).
CONCLUSIONS: Patients with PA had significant HRU and economic burden compared to controls without PA across age strata, primarily driven by a higher burden of hospitalization. Development of efficacious treatments for PA to help reduce the burden is needed.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
EE699
Topic
Economic Evaluation, Study Approaches
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), Rare & Orphan Diseases